Rosen Law Firm said it is continuing to investigate potential securities claims on behalf of Disc Medicine, Inc. shareholders after the company’s Nasdaq-listed shares fell 22% on Feb. 13, 2026. The decline followed a Complete Response Letter from the U.S. Food and Drug Administration stating that it could not approve Disc Medicine’s new drug application for its bitopertin program because the application contained uncertainties requiring additional evidence. Rosen is preparing a prospective class action seeking recovery of investor losses and said eligible purchasers may pursue compensation without upfront fees or costs through a contingency fee arrangement. The firm provided contact details for investors and described its securities litigation experience, while noting that prior results do not guarantee a similar outcome.